Consuelo Buttigliero

Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trial

Johann S. de Bono, Niven Mehra, Giorgio V. Scagliotti et al. · The Lancet Oncology · 2021 · 269 citations · Full text

Urology, Genitourinary Cancer, Medicine +6

Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

Thomas Powles, Piotr Tomczak, Se Hoon Park et al. · The Lancet Oncology · 2022 · 262 citations · Full text

Nivolumab in Combination with Stereotactic Body Radiotherapy in Pretreated Patients with Metastatic Renal Cell Carcinoma. Results of the Phase II NIVES Study

Cristina Masini, Cinzia Iotti, Ugo De Giorgi et al. · European Urology · 2021 · 99 citations · Full text

Pretreated Patients, Urology, Radiation Medicine +6

Management of Patients with Advanced Prostate Cancer. Report from the 2024 Advanced Prostate Cancer Consensus Conference (APCCC)

Silke Gillessen, Fabio Turco, Ian D. Davis et al. · European Urology · 2024 · 87 citations · Full text

Clinical Outcomes of Castration-resistant Prostate Cancer Treatments Administered as Third or Fourth Line Following Failure of Docetaxel and Other Second-line Treatment: Results of an Italian Multicentre Study

Orazio Caffo, Ugo De Giorgi, Lucia Fratino et al. · European Urology · 2014 · 83 citations · Full text

Italian Multicentre Study, Urology, Genitourinary Cancer +9